237 related articles for article (PubMed ID: 35378710)
61. The PRKD1 promoter is a target of the KRas-NF-κB pathway in pancreatic cancer.
Döppler H; Panayiotou R; Reid EM; Maimo W; Bastea L; Storz P
Sci Rep; 2016 Sep; 6():33758. PubMed ID: 27649783
[TBL] [Abstract][Full Text] [Related]
62. MT1-MMP cooperates with Kras(G12D) to promote pancreatic fibrosis through increased TGF-β signaling.
Krantz SB; Shields MA; Dangi-Garimella S; Cheon EC; Barron MR; Hwang RF; Rao MS; Grippo PJ; Bentrem DJ; Munshi HG
Mol Cancer Res; 2011 Oct; 9(10):1294-304. PubMed ID: 21856775
[TBL] [Abstract][Full Text] [Related]
63. ACAGT-007a, an ERK MAPK Signaling Modulator, in Combination with AKT Signaling Inhibition Induces Apoptosis in KRAS Mutant Pancreatic Cancer T3M4 and MIA-Pa-Ca-2 Cells.
Khandakar GI; Satoh R; Takasaki T; Fujitani K; Tanabe G; Sakai K; Nishio K; Sugiura R
Cells; 2022 Feb; 11(4):. PubMed ID: 35203351
[TBL] [Abstract][Full Text] [Related]
64. An exosome-mimicking membrane hybrid nanoplatform for targeted treatment toward Kras-mutant pancreatic carcinoma.
Deng L; Zhang H; Zhang Y; Luo S; Du Z; Lin Q; Zhang Z; Zhang L
Biomater Sci; 2021 Aug; 9(16):5599-5611. PubMed ID: 34250995
[TBL] [Abstract][Full Text] [Related]
65. Co-dependency between KRAS addiction and ARHGEF2 promotes an adaptive escape from MAPK pathway inhibition.
Kent OA; Sandi MJ; Rottapel R
Small GTPases; 2019 Nov; 10(6):441-448. PubMed ID: 28656876
[TBL] [Abstract][Full Text] [Related]
66. Disruption of p16 and activation of Kras in pancreas increase ductal adenocarcinoma formation and metastasis in vivo.
Qiu W; Sahin F; Iacobuzio-Donahue CA; Garcia-Carracedo D; Wang WM; Kuo CY; Chen D; Arking DE; Lowy AM; Hruban RH; Remotti HE; Su GH
Oncotarget; 2011 Nov; 2(11):862-73. PubMed ID: 22113502
[TBL] [Abstract][Full Text] [Related]
67. Glycolysis regulates KRAS plasma membrane localization and function through defined glycosphingolipids.
Liu J; van der Hoeven R; Kattan WE; Chang JT; Montufar-Solis D; Chen W; Wong M; Zhou Y; Lebrilla CB; Hancock JF
Nat Commun; 2023 Jan; 14(1):465. PubMed ID: 36709325
[TBL] [Abstract][Full Text] [Related]
68. EGFR-Pak Signaling Selectively Regulates Glutamine Deprivation-Induced Macropinocytosis.
Lee SW; Zhang Y; Jung M; Cruz N; Alas B; Commisso C
Dev Cell; 2019 Aug; 50(3):381-392.e5. PubMed ID: 31257175
[TBL] [Abstract][Full Text] [Related]
69. Maintenance of acinar cell organization is critical to preventing Kras-induced acinar-ductal metaplasia.
Shi G; DiRenzo D; Qu C; Barney D; Miley D; Konieczny SF
Oncogene; 2013 Apr; 32(15):1950-8. PubMed ID: 22665051
[TBL] [Abstract][Full Text] [Related]
70. Metabolic functions of macropinocytosis.
Palm W
Philos Trans R Soc Lond B Biol Sci; 2019 Feb; 374(1765):20180285. PubMed ID: 30967008
[TBL] [Abstract][Full Text] [Related]
71. Mutant KRAS Downregulates the Receptor for Leukemia Inhibitory Factor (LIF) to Enhance a Signature of Glycolysis in Pancreatic Cancer and Lung Cancer.
Liu S; Gandler HI; Tošić I; Ye DQ; Giaccone ZT; Frank DA
Mol Cancer Res; 2021 Aug; 19(8):1283-1295. PubMed ID: 33931487
[TBL] [Abstract][Full Text] [Related]
72. Critical role of hnRNP A1 in activating KRAS transcription in pancreatic cancer cells: A molecular mechanism involving G4 DNA.
Cogoi S; Rapozzi V; Cauci S; Xodo LE
Biochim Biophys Acta Gen Subj; 2017 May; 1861(5 Pt B):1389-1398. PubMed ID: 27888145
[TBL] [Abstract][Full Text] [Related]
73. Regulation of macropinocytosis by p21-activated kinase-1.
Dharmawardhane S; Schürmann A; Sells MA; Chernoff J; Schmid SL; Bokoch GM
Mol Biol Cell; 2000 Oct; 11(10):3341-52. PubMed ID: 11029040
[TBL] [Abstract][Full Text] [Related]
74. Aurora A kinase and its activator TPX2 are potential therapeutic targets in KRAS-induced pancreatic cancer.
Gomes-Filho SM; Dos Santos EO; Bertoldi ERM; Scalabrini LC; Heidrich V; Dazzani B; Levantini E; Reis EM; Bassères DS
Cell Oncol (Dordr); 2020 Jun; 43(3):445-460. PubMed ID: 32193808
[TBL] [Abstract][Full Text] [Related]
75. Plasma membrane V-ATPase controls oncogenic RAS-induced macropinocytosis.
Ramirez C; Hauser AD; Vucic EA; Bar-Sagi D
Nature; 2019 Dec; 576(7787):477-481. PubMed ID: 31827278
[TBL] [Abstract][Full Text] [Related]
76. Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis.
Santana-Codina N; Roeth AA; Zhang Y; Yang A; Mashadova O; Asara JM; Wang X; Bronson RT; Lyssiotis CA; Ying H; Kimmelman AC
Nat Commun; 2018 Nov; 9(1):4945. PubMed ID: 30470748
[TBL] [Abstract][Full Text] [Related]
77. Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma.
Ju HQ; Ying H; Tian T; Ling J; Fu J; Lu Y; Wu M; Yang L; Achreja A; Chen G; Zhuang Z; Wang H; Nagrath D; Yao J; Hung MC; DePinho RA; Huang P; Xu RH; Chiao PJ
Nat Commun; 2017 Feb; 8():14437. PubMed ID: 28232723
[TBL] [Abstract][Full Text] [Related]
78. Rac is required for constitutive macropinocytosis by dendritic cells but does not control its downregulation.
West MA; Prescott AR; Eskelinen EL; Ridley AJ; Watts C
Curr Biol; 2000 Jul; 10(14):839-48. PubMed ID: 10899002
[TBL] [Abstract][Full Text] [Related]
79. Synergistic blocking of RAS downstream signaling and epigenetic pathway in
Zhang X; Mao T; Xu H; Li S; Yue M; Ma J; Yao J; Wang Y; Zhang X; Ge W; Wang Y; Shentu D; Wang L
Aging (Albany NY); 2022 Apr; 14(8):3597-3606. PubMed ID: 35468095
[TBL] [Abstract][Full Text] [Related]
80. SOX9 activity is induced by oncogenic Kras to affect MDC1 and MCMs expression in pancreatic cancer.
Zhou H; Qin Y; Ji S; Ling J; Fu J; Zhuang Z; Fan X; Song L; Yu X; Chiao PJ
Oncogene; 2018 Feb; 37(7):912-923. PubMed ID: 29059173
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
